🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Day 1 #GU24 ASCO Highlights #CommunityOncology 1. #CONTAC02: Atezo/Cabo mCRPC 2. #BRCAAWAY: PARPi in mCRPC 3. #EMBARK: High Risk biochemical recurrence #ProstateCancer cancer #OncEd #MedEd #OncTwitter #MedTwitter #gusm 1/4

Enfortumab Vedotin + pembro shows broad spectrum of activity for RR PFS and OS in all subgroups. This includes subsets such as lymph node disease, liver mets, PD-L1 status, upper tract disease, platinum eligibility. This +ve data underlines EVP as a new standard of care #GU24

Adjuvant pembro ⬆️ DFS (0.69) but ❌ OS (0.98) in UC, ~10% tox ++. Atezo also had ❌ OS. Nivo had 0.7 DFS but no OS data after ++ years-assuming it’s +ve seems unwise. Without OS we’re over treating. Adjuvant IO in all comers is on shaky ground without more data IMO #GU24

51 years in the making till #GU24. OS benefit in adjuvant Renal Cancer is finally here. #KYN564

Proud of IMDC posters by Renee Maria Saliby #connorwells #mehulgupta who all won ASCO merit awards! 1145 IPI/nivo patient outcomes, treatment free survival and intermediate endpoints. Check it out! #awesomefellows @oncoalert ASCO UCalgaryMedicine #GU24 Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology

Day 3 #GU24 ASCO Highlights #CommunityOncology 1. #KN564: Adj Pembro w/ +ve OS 2. #LITESPARK005 3. #Updates in RCC: - CM214 - CM9ER - CLEAR - SubC Nivo #OncEd #MedEd #OncTwitter #MedTwitter #gusm #kidneycancer #ThatsaWrap 1/4

Delighted to announce that our new paper has been published European Urology! Brain mets were found in 389/4799 (8.1%) mRCC pts and intensive systemic/focal therapies were associated with better prognosis. Special thanks to Toni Choueiri, MD Daniel Heng and other collaborators IMDC

#GU24 ASCO RCC highlights: 1⃣The phase 3 KEYNOTE-564 Toni Choueiri, MD This landmark study demonstrated a significant improvement in overall survival compared to placebo, marking it as the first to show such a meaningful survival benefit with adjuvant therapy in RCC! 2⃣The

Updated table of IO combos (ITT population) in front line mRCC after #ASCOGU24. Has anything changed for you based on these data?

New radiotracer for clear cell renal carcinoma - CA-9 targeting peptide: SUVs >100 in tumor in first 3 patients with low background activity = WOW !! jnm.snmjournals.org/content/early/… Debiopharm Ben Tran JNM Peter Mac Research

So proud to see the diffusion of our review on ADC toxicities, with already 25k accesses and >300 Altmetric! The article will be made free to access and download in the days surrounding #AACR24, starting today: download a copy if you have interest in ADCs! nature.com/articles/s4157…

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24

ENZA-P in The Lancet Oncology Lu-177 PSMA-617 + enzalutamide vs. enza alone: ● ↑PFS: 13.0 vs 7.8, hazard radio 0.43 ● PSA90 response 78% vs 37% ● PSA50 response 93% vs. 68% ● no additional side effects Incredible work from Louise Emmett Ian Davis & ANZUP team

Pleased to share our latest work published in Urologic Oncology focusing on precision medicine in #ProstateCancer Link 👇 authors.elsevier.com/c/1iwC7_OWv~Zu… Anis Hamid Christopher Sweeney, MBBS Peter Mac Research

1/ The long-awaited OS results from #KEYNOTE-564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC. nejm.org/doi/full/10.10…

TROPICS-4 (sacituzumab govitecan vs chemo) in heavily pretreated bladder cancer missed OS. Many drugs have failed in this space (personal experience +++). Managing toxicity is important. Earlier treatment & combinations may yield different results #ASCO24 gilead.com/news-and-press…

Come see our #IMDC fellow @Martinzarba Saturday 8am Room S100bc present on the Favorable risk and VERY favorable risk metastatic #kidneycancer population for potential guidance on therapy selection. #IMDConline Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Tom Powles Ravindran Kanesvaran OncoAlert #ASCO24

The one and only Tom Powles presenting data from the #KeyNote361 trial 🚨#ctDNA reductions were associated with improved ORR, PFS (P< 0.001), and OS (P< 0.01) in pts with previously untreated advanced UC on chemo 🚨 Changes with #pembro were more associated with long-term

HER2: a remarkable story of precision oncology. Check this wonderful Nature review on targeting HER2 beyond breast. 👉Important to remember: now that we have an agnostic anti-HER2 drug approved (T-DXd), every adv cancer patient should get HER2 testing! nature.com/articles/s4157…

Navigating DOAC dosing around surgeries? JAMA OncoAlert #Anticoagulation #surgery #oncology doi:10.1001/jama.2024.12708